Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study

Basit Öğe Kaydı
dc.authorid0000-0002-6265-5227en_US
dc.authorid0000-0002-9983-0308en_US
dc.authorid0000-0002-3217-6305en_US
dc.authorid0000-0002-4294-5999en_US
dc.authorid0000-0003-1635-0016en_US
dc.contributor.authorErdem, Hakan
dc.contributor.authorÇağ, Yasemin
dc.contributor.authorGençer, Serap
dc.contributor.authorUysal, Serhat
dc.contributor.authorKarakurt, Zuhal
dc.contributor.authorHarman, Rezan
dc.contributor.authorAslan, Emel
dc.date.accessioned2024-03-04T13:12:09Z
dc.date.available2024-03-04T13:12:09Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.description.abstractVentilator-associated pneumonia (VAP) due to Acinetobacter spp. is one of the most common infections in the intensive care unit. Hence, we performed this prospective-observational multicenter study, and described the course and outcome of the disease. This study was performed in 24 centers between January 06, 2014, and December 02, 2016. The patients were evaluated at time of pneumonia diagnosis, when culture results were available, and at 72 h, at the 7th day, and finally at the 28th day of follow-up. Patients with coexistent infections were excluded and only those with a first VAP episode were enrolled. Logistic regression analysis was performed. A total of 177 patients were included; empiric antimicrobial therapy was appropriate (when the patient received at least one antibiotic that the infecting strain was ultimately shown to be susceptible) in only 69 (39%) patients. During the 28-day period, antibiotics were modified for side effects in 27 (15.2%) patients and renal dose adjustment was made in 38 (21.5%). Ultimately, 89 (50.3%) patients died. Predictors of mortality were creatinine level (OR, 1.84 (95% CI 1.279–2.657); p = 0.001), fever (OR, 0.663 (95% CI 0.454–0.967); p = 0.033), malignancy (OR, 7.095 (95% CI 2.142–23.500); p = 0.001), congestive heart failure (OR, 2.341 (95% CI 1.046–5.239); p = 0.038), appropriate empiric antimicrobial treatment (OR, 0.445 (95% CI 0.216–0.914); p = 0.027), and surgery in the last month (OR, 0.137 (95% CI 0.037–0.499); p = 0.003). Appropriate empiric antimicrobial treatment in VAP due to Acinetobacter spp. was associated with survival while renal injury and comorbid conditions increased mortality. Hence, early diagnosis and appropriate antibiotic therapy remain crucial to improve outcomes.en_US
dc.identifier.citationErdem, H., Çağ, Y., Gençer, S., Uysal, S., Karakurt, Z., Harman, R. ve diğerleri. (2020). Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study. European Journal of Clinical Microbiology and Infectious Diseases, 39(1), 45-52.en_US
dc.identifier.doi10.1007/s10096-019-03691-z
dc.identifier.endpage52en_US
dc.identifier.issn0934-9723
dc.identifier.issue1en_US
dc.identifier.pmid31502120
dc.identifier.scopus2-s2.0-85073948773
dc.identifier.scopusqualityQ1
dc.identifier.startpage45en_US
dc.identifier.urihttps://link.springer.com/article/10.1007/s10096-019-03691-z
dc.identifier.urihttps://hdl.handle.net/11468/13499
dc.identifier.volume39en_US
dc.identifier.wosWOS:000511888500006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAslan, Emel
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Journal of Clinical Microbiology and Infectious Diseases
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcinetobacteren_US
dc.subjectMortalityen_US
dc.subjectPneumoniaen_US
dc.subjectTreatmenten_US
dc.subjectVAPen_US
dc.subjectVentilator-associated pneumoniaen_US
dc.titleTreatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI studyen_US
dc.titleTreatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter.pdf
Boyut:
524.79 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu